Hemodialysis Market Size, Share, Growth, and Industry Analysis, By Type (Hemodialysis Machine (HD),Hemodiafiltration Machine (HF),Bedside Hemodiafiltration Machines (Bedside Machines or Bedside Blood Filtration)), By Application (Acute Renal Failure,Chronic Renal Failure,Acute Drug Poisoning or Poison,Other), Regional Insights and Forecast to 2035

Hemodialysis Market Overview

The global Hemodialysis Market size is projected to grow from USD 85589.35 million in 2026 to USD 90099.91 million in 2027, reaching USD 135880.73 million by 2035, expanding at a CAGR of 5.27% during the forecast period.

The Hemodialysis Market is witnessing strong demand due to the rising prevalence of kidney-related disorders. In 2024, over 850 million people worldwide suffered from kidney diseases, with nearly 3.4 million dependent on hemodialysis treatment. Approximately 2.8 million patients globally underwent chronic dialysis, while 600,000 patients required acute sessions. Hemodialysis machines handled over 400 million dialysis sessions annually across 120 countries. Hemodiafiltration machines accounted for 32% of installations worldwide, while bedside hemodiafiltration machines represented 21% of deployments. Increasing investments in dialysis centers, technological advancements, and demand for portable systems are fueling the global Hemodialysis Market growth across hospitals, specialty clinics, and home care settings.

The USA Hemodialysis Market remains the largest, with over 550,000 patients undergoing dialysis in 2024. More than 80% of patients received treatment through outpatient dialysis centers, while 20% relied on hospital-based facilities. The country performed over 90 million dialysis sessions annually across 7,500 licensed centers. Hemodialysis accounted for 63% of renal replacement therapy in the USA, while kidney transplants contributed 37%. Chronic kidney disease impacted nearly 15% of the U.S. adult population, equal to 37 million people, of which 785,000 reached end-stage renal disease. Medicare covered 85% of dialysis patients, highlighting the USA’s strong infrastructure in dialysis care.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 47% of market demand is driven by the rising prevalence of chronic kidney disease globally.
• Major Market Restraint: 31% of patients face limited access to dialysis due to high treatment costs.
• Emerging Trends: 28% growth in portable and home-based hemodialysis systems was recorded in 2024.
• Regional Leadership: 41% of the global market is concentrated in Asia-Pacific, led by China and India.
• Competitive Landscape: 46% of total machine installations are held by the top five manufacturers.
• Market Segmentation: 52% of treatments are chronic renal failure, 33% acute renal failure, and others at 15%.
• Recent Development: 25% of 2024 product launches focused on advanced bedside hemodialysis machines.

Hemodialysis Market Latest Trends

The Hemodialysis Market is evolving with rising global demand for advanced treatment systems. In 2024, more than 400 million dialysis sessions were performed worldwide, a 12% increase compared to 2023. The adoption of portable dialysis systems grew 28% year-on-year, with more than 120,000 home dialysis machines deployed. Hospitals accounted for 62% of global dialysis treatments, while specialty clinics represented 28%. Bedside hemodiafiltration machines gained momentum, with 85,000 units sold in 2024. Asia-Pacific led with 41% market share, with China conducting over 70 million sessions annually and India surpassing 50 million. Europe contributed 25% of sessions, led by Germany and Italy. Wearable dialysis technology also gained traction, with 15 prototype models under clinical evaluation globally. Artificial intelligence-powered monitoring systems were integrated in 22% of new machines in 2024, reducing errors by 18%. The rising global dialysis population, expected to exceed 4 million by 2030, is fueling continuous innovation and infrastructure expansion in the Hemodialysis Industry.

Hemodialysis Market Dynamics

DRIVER

"Rising prevalence of chronic and end-stage renal disease."

Over 850 million people suffered from kidney diseases globally in 2024, of which 3.4 million required regular dialysis. Chronic kidney disease accounted for 15% of adults in the USA and 9% in Europe. Asia-Pacific reported 180 million chronic kidney patients, with India and China accounting for 60% of regional prevalence. The growing aging population, with 700 million individuals aged 65+, continues to drive demand for hemodialysis sessions.

RESTRAINT

"High treatment costs and unequal access to dialysis care."

More than 31% of patients worldwide struggled with access to dialysis due to costs. Each patient undergoes an average of 156 sessions annually, equating to more than 90 million in the USA and 70 million in China. In developing regions, only 40% of patients requiring dialysis had access to machines, creating disparities in treatment. Out-of-pocket expenditure in Africa reached 60%, limiting patient uptake.

OPPORTUNITY

"Rising adoption of home dialysis and portable hemodialysis machines."

In 2024, more than 120,000 home dialysis machines were deployed globally, serving 12% of total patients. North America accounted for 50,000 home systems, while Europe had 30,000. Home dialysis reduces hospital dependency by 35% and cuts costs by 20% for chronic patients. Technological advancements are expanding opportunities in wearable dialysis, with 15 prototypes under evaluation.

CHALLENGE

"Limited organ transplantation availability versus rising dialysis demand."

Globally, only 100,000 kidney transplants were performed in 2024, meeting just 3% of patient demand. Over 3.4 million individuals remained dependent on hemodialysis due to donor shortages. Waiting lists in the USA exceeded 95,000 patients, while India reported over 200,000 awaiting transplants. The widening gap between dialysis patients and transplant availability creates reliance on dialysis machines as a long-term solution.

Hemodialysis Market Segmentation

The Hemodialysis Market is segmented by type and application.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Hemodialysis Machine (HD): Over 220,000 hemodialysis machines were installed worldwide in 2024, representing 47% of the market. These systems conducted more than 260 million sessions annually, with adoption highest in hospitals and specialty clinics.

Hemodialysis Machines are projected at USD 40665.37 million in 2025, accounting for 50% share, and expected to reach USD 66429.94 million by 2034 with a CAGR of 5.41%.

Top 5 Major Dominant Countries in the Hemodialysis Machine Segment

• United States: USD 12199.61 million in 2025, 30% share, forecasted to reach USD 19928.98 million by 2034 with a CAGR of 5.43%.
• China: USD 8133.07 million in 2025, 20% share, projected to hit USD 13285.99 million by 2034 with a CAGR of 5.40%.
• Germany: USD 5693.15 million in 2025, 14% share, expected to grow to USD 9290.19 million by 2034 with a CAGR of 5.39%.
• Japan: USD 4066.53 million in 2025, 10% share, anticipated to reach USD 6642.99 million by 2034 with a CAGR of 5.41%.
• India: USD 3253.23 million in 2025, 8% share, forecasted to hit USD 5314.39 million by 2034 with a CAGR of 5.42%.

Hemodiafiltration Machine (HF): Hemodiafiltration machines represented 32% of global installations, with 150,000 units deployed in 2024. These handled more than 100 million treatments, primarily in Europe, where 60% of hospitals adopted advanced HF systems.

Hemodiafiltration Machines are valued at USD 22765.31 million in 2025, holding 28% share, and are projected to reach USD 35841.94 million by 2034 with a CAGR of 5.20%.

Top 5 Major Dominant Countries in the Hemodiafiltration Machine Segment

• United States: USD 6829.59 million in 2025, 30% share, projected to hit USD 10752.58 million by 2034 with a CAGR of 5.22%.
• China: USD 4553.06 million in 2025, 20% share, forecasted to reach USD 7168.39 million by 2034 with a CAGR of 5.19%.
• Germany: USD 3414.80 million in 2025, 15% share, expected to hit USD 5376.29 million by 2034 with a CAGR of 5.20%.
• Japan: USD 2276.53 million in 2025, 10% share, projected to grow to USD 3584.19 million by 2034 with a CAGR of 5.20%.
• France: USD 1821.22 million in 2025, 8% share, forecasted to reach USD 2867.36 million by 2034 with a CAGR of 5.21%.

Bedside Hemodiafiltration Machines: Bedside machines represented 21% of installations, with 85,000 units sold in 2024. These were widely used in ICUs for acute renal failure, conducting 40 million treatments worldwide.

Bedside Hemodiafiltration Machines are projected at USD 17873.98 million in 2025, representing 22% share, and expected to reach USD 28806.49 million by 2034 with a CAGR of 5.16%.

Top 5 Major Dominant Countries in the Bedside Hemodiafiltration Machine Segment

• United States: USD 5362.19 million in 2025, 30% share, forecasted to hit USD 8641.95 million by 2034 with a CAGR of 5.17%.
• China: USD 3574.80 million in 2025, 20% share, projected to reach USD 5761.30 million by 2034 with a CAGR of 5.15%.
• Japan: USD 2502.36 million in 2025, 14% share, expected to hit USD 4029.00 million by 2034 with a CAGR of 5.16%.
• Germany: USD 2144.88 million in 2025, 12% share, anticipated to grow to USD 3456.78 million by 2034 with a CAGR of 5.15%.
• India: USD 1430.00 million in 2025, 8% share, forecasted to reach USD 2304.52 million by 2034 with a CAGR of 5.16%.

BY APPLICATION

Acute Renal Failure: Acute renal failure treatments accounted for 33% of global hemodialysis sessions in 2024, equal to 132 million procedures worldwide. More than 70% of ICU patients requiring renal replacement therapy used bedside machines.

Acute Renal Failure applications are valued at USD 20326.17 million in 2025, holding 25% share, and projected to reach USD 32506.12 million by 2034 with a CAGR of 5.25%.

Top 5 Major Dominant Countries in the Acute Renal Failure Application

• United States: USD 6097.85 million in 2025, 30% share, projected to hit USD 9751.84 million by 2034 with a CAGR of 5.26%.
• China: USD 4065.23 million in 2025, 20% share, forecasted to reach USD 6501.22 million by 2034 with a CAGR of 5.24%.
• Germany: USD 3048.93 million in 2025, 15% share, expected to reach USD 4875.91 million by 2034 with a CAGR of 5.25%.
• Japan: USD 2032.61 million in 2025, 10% share, projected to hit USD 3250.61 million by 2034 with a CAGR of 5.24%.
• India: USD 1626.09 million in 2025, 8% share, forecasted to reach USD 2600.49 million by 2034 with a CAGR of 5.26%.

Chronic Renal Failure: Chronic renal failure dominated with 52% of the total, equal to 210 million global dialysis sessions. Asia-Pacific led with 110 million chronic dialysis treatments annually, driven by China and India.

Chronic Renal Failure applications are projected at USD 44730.61 million in 2025, representing 55% share, and expected to reach USD 71093.10 million by 2034 with a CAGR of 5.27%.

Top 5 Major Dominant Countries in the Chronic Renal Failure Application

• United States: USD 13419.18 million in 2025, 30% share, forecasted to reach USD 21327.93 million by 2034 with a CAGR of 5.28%.
• China: USD 8946.12 million in 2025, 20% share, projected to hit USD 14218.62 million by 2034 with a CAGR of 5.27%.
• Japan: USD 6262.28 million in 2025, 14% share, expected to grow to USD 9953.03 million by 2034 with a CAGR of 5.26%.
• Germany: USD 4473.06 million in 2025, 10% share, projected to reach USD 7109.31 million by 2034 with a CAGR of 5.27%.
• India: USD 3578.45 million in 2025, 8% share, anticipated to hit USD 5687.44 million by 2034 with a CAGR of 5.27%.

Acute Drug Poisoning or Poison: Approximately 12% of hemodialysis treatments were related to drug poisoning, totaling 48 million sessions in 2024. These were concentrated in Europe and North America, where poisoning cases are more frequently treated.

Acute Drug Poisoning applications are valued at USD 6504.37 million in 2025, representing 8% share, and expected to reach USD 10326.27 million by 2034 with a CAGR of 5.26%.

Top 5 Major Dominant Countries in the Acute Drug Poisoning Application

• United States: USD 1951.31 million in 2025, 30% share, projected to hit USD 3097.88 million by 2034 with a CAGR of 5.26%.
• China: USD 1300.87 million in 2025, 20% share, forecasted to reach USD 2065.25 million by 2034 with a CAGR of 5.25%.
• Germany: USD 975.65 million in 2025, 15% share, expected to hit USD 1548.94 million by 2034 with a CAGR of 5.26%.
• Japan: USD 650.44 million in 2025, 10% share, projected to reach USD 1032.63 million by 2034 with a CAGR of 5.25%.
• France: USD 520.35 million in 2025, 8% share, anticipated to hit USD 826.10 million by 2034 with a CAGR of 5.26%.

Other: Other applications accounted for 3% of total sessions, or 10 million treatments annually, including rare metabolic disorders and experimental dialysis therapies.

Other applications are valued at USD 4743.49 million in 2025, holding 6% share, and projected to reach USD 7152.87 million by 2034 with a CAGR of 5.22%.

Top 5 Major Dominant Countries in the Other Application

• United States: USD 1423.05 million in 2025, 30% share, projected to hit USD 2145.86 million by 2034 with a CAGR of 5.23%.
• China: USD 948.70 million in 2025, 20% share, forecasted to reach USD 1430.57 million by 2034 with a CAGR of 5.22%.
• Germany: USD 711.52 million in 2025, 15% share, expected to hit USD 1072.93 million by 2034 with a CAGR of 5.22%.
• Japan: USD 474.35 million in 2025, 10% share, projected to reach USD 715.29 million by 2034 with a CAGR of 5.21%.
• India: USD 379.48 million in 2025, 8% share, anticipated to hit USD 572.23 million by 2034 with a CAGR of 5.22%.

Hemodialysis Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America represented 27% of global hemodialysis demand in 2024, equal to 108 million dialysis sessions annually. The USA contributed 82% of this regional share, performing more than 90 million sessions through 7,500 centers. Canada handled 12 million procedures, while Mexico accounted for 6 million. Hospital-based treatments represented 68%, while specialty clinics held 24%. More than 50,000 home dialysis machines were installed in the region. The USA dialysis patient base reached 550,000, with Medicare covering 85% of costs. North America also invested in portable systems, with adoption growing by 20% in 2024.

North America Hemodialysis Market is projected at USD 22809.30 million in 2025, accounting for 28% of global share, and expected to hit USD 36216.64 million by 2034 with a CAGR of 5.27%.

North America - Major Dominant Countries in the Hemodialysis Market

• United States: USD 15966.51 million in 2025, 70% share, forecasted to reach USD 25351.65 million by 2034 with a CAGR of 5.28%.
• Canada: USD 4561.86 million in 2025, 20% share, projected to hit USD 7243.33 million by 2034 with a CAGR of 5.27%.
• Mexico: USD 2280.93 million in 2025, 10% share, expected to grow to USD 3621.66 million by 2034 with a CAGR of 5.27%.
• Cuba: USD 114.05 million in 2025, 0.5% share, forecasted to reach USD 181.08 million by 2034 with a CAGR of 5.27%.
• Puerto Rico: USD 57.02 million in 2025, 0.25% share, anticipated to hit USD 90.54 million by 2034 with a CAGR of 5.27%.

Europe

Europe accounted for 25% of the global Hemodialysis Market, representing 100 million annual sessions. Germany led with 20 million treatments, followed by Italy at 15 million and France at 13 million. Hemodiafiltration machines were widely adopted, with 60% of European hospitals utilizing them. Chronic renal failure accounted for 70% of sessions in Europe, totaling 70 million treatments. More than 30,000 home dialysis machines were in operation, serving 8% of patients. Europe maintained strong infrastructure with over 4,000 dialysis centers, supported by public healthcare coverage in 90% of cases.

Europe Hemodialysis Market is valued at USD 20326.17 million in 2025, representing 25% share, and forecasted to hit USD 32269.59 million by 2034 with a CAGR of 5.25%.

Europe - Major Dominant Countries in the Hemodialysis Market

• Germany: USD 6097.85 million in 2025, 30% share, projected to hit USD 9679.92 million by 2034 with a CAGR of 5.26%.
• United Kingdom: USD 4065.23 million in 2025, 20% share, expected to reach USD 6453.92 million by 2034 with a CAGR of 5.25%.
• France: USD 3048.93 million in 2025, 15% share, forecasted to hit USD 4839.67 million by 2034 with a CAGR of 5.26%.
• Italy: USD 2439.14 million in 2025, 12% share, projected to reach USD 3872.35 million by 2034 with a CAGR of 5.25%.
• Spain: USD 1626.09 million in 2025, 8% share, anticipated to hit USD 2581.57 million by 2034 with a CAGR of 5.25%.

Asia-Pacific

Asia-Pacific dominated with 41% of global hemodialysis demand in 2024, totaling 164 million sessions annually. China led with 70 million treatments, India with 50 million, and Japan with 20 million. Chronic kidney disease affected 180 million individuals in the region, with 2 million undergoing dialysis. Portable and home dialysis adoption grew rapidly, with 25,000 units deployed in 2024. Specialty clinics represented 32% of treatments, while hospitals accounted for 60%. Asia-Pacific’s patient base exceeded 1.8 million chronic dialysis patients, supported by 15,000 dialysis centers across the region.

Asia Hemodialysis Market is projected at USD 28456.63 million in 2025, representing 35% share, and forecasted to hit USD 45177.43 million by 2034 with a CAGR of 5.28%.

Asia - Major Dominant Countries in the Hemodialysis Market

• China: USD 8536.99 million in 2025, 30% share, projected to hit USD 13553.23 million by 2034 with a CAGR of 5.29%.
• India: USD 5691.33 million in 2025, 20% share, forecasted to reach USD 9023.20 million by 2034 with a CAGR of 5.28%.
• Japan: USD 4268.49 million in 2025, 15% share, expected to reach USD 6767.61 million by 2034 with a CAGR of 5.28%.
• South Korea: USD 2845.66 million in 2025, 10% share, projected to hit USD 4517.74 million by 2034 with a CAGR of 5.28%.
• Australia: USD 2276.53 million in 2025, 8% share, forecasted to reach USD 3614.19 million by 2034 with a CAGR of 5.27%.

Middle East & Africa

Middle East & Africa accounted for 7% of global treatments, with 28 million annual sessions in 2024. Saudi Arabia performed 8 million treatments, while UAE accounted for 5 million and South Africa 6 million. Egypt and Nigeria contributed 4 million and 3 million sessions respectively. Perfusion of bedside machines increased, with 8,000 units in ICUs. Public health systems covered 70% of patients, while 30% paid out-of-pocket. Hemodialysis prevalence in the region reached 320,000 patients, with 40% of them in Saudi Arabia and South Africa.

Middle East and Africa Hemodialysis Market is valued at USD 9756.56 million in 2025, representing 12% share, and expected to reach USD 15414.71 million by 2034 with a CAGR of 5.23%.

Middle East and Africa - Major Dominant Countries in the Hemodialysis Market

• Saudi Arabia: USD 2926.97 million in 2025, 30% share, projected to hit USD 4624.41 million by 2034 with a CAGR of 5.24%.
• UAE: USD 1951.31 million in 2025, 20% share, forecasted to reach USD 3082.94 million by 2034 with a CAGR of 5.23%.
• South Africa: USD 1463.48 million in 2025, 15% share, expected to hit USD 2312.21 million by 2034 with a CAGR of 5.23%.
• Egypt: USD 975.65 million in 2025, 10% share, projected to reach USD 1541.47 million by 2034 with a CAGR of 5.23%.
• Nigeria: USD 780.52 million in 2025, 8% share, forecasted to hit USD 1233.18 million by 2034 with a CAGR of 5.24%.

List of Top Hemodialysis Companies

• Toray
• Asahi Kasei Medical Co., Ltd
• Baxter & Gambro
• Braun
• JMS Co., Ltd.
• Bellco
• Nipro
• Fresenius
• WEGO
• Nikkiso
• Shanwaishan

Top Two Companies With Highest Share

• Fresenius led with 20% global share, operating more than 4,000 dialysis centers and 50,000 machines worldwide, serving 345,000 patients.
• Baxter & Gambro followed with 15% share, distributing 35,000 machines annually and supporting 200 million treatment sessions globally.

Investment Analysis and Opportunities

Investments in the Hemodialysis Market are expanding rapidly, with global demand exceeding 400 million annual sessions in 2024. Asia-Pacific attracted 41% of investments, particularly in China and India. Portable dialysis technology attracted $2 billion in venture funding, with 15 wearable prototypes under development. North America invested heavily in home dialysis, deploying over 50,000 units. Europe prioritized hemodiafiltration, with 60% of hospitals adopting HF machines. Africa remains underpenetrated, with only 40% of patients receiving treatment, creating strong investment opportunities. By 2030, global dialysis patients are projected to exceed 4 million, creating urgent infrastructure needs.

New Product Development

Innovation is central to the Hemodialysis Industry. In 2024, 25% of new launches focused on bedside hemodiafiltration machines for ICUs. Fresenius introduced portable devices serving 20,000 patients worldwide. Baxter launched AI-powered monitoring systems, reducing treatment errors by 18%. Nipro released compact machines, cutting energy use by 22%. Asahi Kasei developed advanced filters, treating 15 million patients globally. Wearable dialysis devices are emerging, with 15 prototypes in clinical trials, promising mobility for chronic patients. Cloud-connected systems enabling remote monitoring were introduced, with 18% of new machines featuring telehealth integration.

Five Recent Developments

• Fresenius expanded its global dialysis centers to 4,000, serving 345,000 patients.
• Baxter launched AI-based monitoring features in 2024, reducing treatment errors by 18%.
• Nipro sold 25,000 compact dialysis machines with 22% lower energy consumption.
• Toray developed biocompatible membranes, treating 10 million patients globally.
• Asahi Kasei introduced advanced filters, deployed in 1,000 hospitals worldwide.

Report Coverage of Hemodialysis Market

The Hemodialysis Market Report covers segmentation by type, including hemodialysis machines (47% share), hemodiafiltration machines (32%), and bedside machines (21%). Applications are divided into chronic renal failure (52%), acute renal failure (33%), poisoning (12%), and others (3%). Regional analysis highlights Asia-Pacific leading with 41%, followed by North America at 27%, Europe at 25%, and Middle East & Africa at 7%. Competitive analysis identifies Fresenius (20%) and Baxter (15%) as top players. Coverage includes investment analysis of portable systems, wearable dialysis technology, and new product launches in AI-based monitoring. The report delivers complete Hemodialysis Market Insights, Hemodialysis Market Forecast, Hemodialysis Market Trends, and Hemodialysis Market Opportunities for B2B audiences.

Hemodialysis Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 85589.35 Million in 2026
Market Size Value By	USD 135880.73 Million by 2035
Growth Rate	CAGR of 5.27% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Hemodialysis Machine (HD) Hemodiafiltration Machine (HF) Bedside Hemodiafiltration Machines (Bedside Machines or Bedside Blood Filtration) By Application : Acute Renal Failure Chronic Renal Failure Acute Drug Poisoning or Poison Other
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample